Axios @axios
More than 90% of people with Alzheimer's disease are 65 and older, which means Medicare (i.e., taxpayers) will shoulder the load for the new FDA-approved drug Aduhelm's $56,000 annual list price. https://t.co/ZC5reZyh1y — PolitiTweet.org